Related Experiment Video
Updated: Jun 19, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole
Oliver Sartor1, Mari Nakabayashi, Mary-Ellen Taplin
1Dana-Farber Cancer Institute, Boston, MA, USA. osartor@tulane.edu
Background:
Ketoconazole is a commonly used secondary hormonal therapy in castration-refractory prostate cancer (CRPC), but disease progression inevitably occurs. Both prostatic and metastatic lesions in patients with CRPC overexpress 5-alpha reductase (SRDA5) type I. We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone.
Patients And Methods:
A total of 10 patients with CRPC with progression after ketoconazole treatment were treated with a combination of ketoconazole plus dutasteride 0.5 mg/day, a dual SRDA5 inhibitor.
Results:
After dutasteride addition, 8 (80%) of the 10 patients had varying degrees of prostate-specific antigen (PSA) decline relative to baseline. Median progression-free survival after dutasteride addition was 4.9 months (range, 2.7+ to 9.8 months); no patient had a >OR= 50% PSA decline.
Conclusion:
We conclude that dutasteride added to ketoconazole at the time progression might prolong time to PSA progression in patients with CRPC.
